Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.
about
Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptidesPersistent pharmacokinetic challenges to pediatric drug developmentNovel mechanism of impaired function of organic anion-transporting polypeptide 1B3 in human hepatocytes: post-translational regulation of OATP1B3 by protein kinase C activation.The physiological role of drug transporters.Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug InteractionsMass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).Organic anion-transporting polypeptides.In vitro methods to support transporter evaluation in drug discovery and development.Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1.Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions.Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.Micropatterned Co-Cultures of Human Hepatocytes and Stromal Cells for the Assessment of Drug Clearance and Drug-Drug Interactions.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.From the Cover: Identification of Natural Products as Inhibitors of Human Organic Anion Transporters (OAT1 and OAT3) and Their Protective Effect on Mercury-Induced Toxicity.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.Exploring Chronic Drug Effects on Microengineered Human Liver Cultures Using Global Gene Expression Profiling.Tetronic® 904-containing polymeric micelles overcome the overexpression of ABCG2 in the blood-brain barrier of rats and boost the penetration of the antiretroviral efavirenz into the CNS.Drug Transporters: Advances and Opportunities.Role of Hepatic Drug Transporters in Drug Development.Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans.Characterization of Liver- and Cancer-type-Organic Anion Transporting Polypeptide (OATP) 1B3 Messenger RNA Expression in Normal and Cancerous Human Tissues.Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.OCT1 mediates hepatic uptake of sumatriptan and loss-of-functionOCT1polymorphisms affect sumatriptan pharmacokineticsEfavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
P2860
Q24564462-D3322FC2-2786-479C-9946-19D1EBA3FE29Q27023912-BC63867F-6407-4B2E-95D9-AD7F00965BBCQ34360004-044743CC-18A2-4FDE-933D-94FAEF857FF9Q35563701-BC738346-2564-4718-8421-BD236B622D74Q37114554-DA6B0F11-A0AF-4CF3-9D08-F591E41FE442Q37145705-4F3162E0-9CC7-496D-AD8E-69DF8E1199BFQ37207759-E52022AE-7BDE-4681-8DCD-2ECBD2001E52Q37598626-F832CB97-7DCD-4270-BBDD-FBC9E265D57CQ37718185-4FA582BE-BE50-4298-AB79-ED03D59A612DQ38099194-DFCA7294-AFDD-4BE3-BDFA-602B21AB6A20Q38200490-C6F51BA1-6B37-49F9-8B87-4B3FD9F1F541Q38214334-5425EDCA-CE56-4C8D-9EE9-B4FA35F3E074Q38793280-9B02288D-AFD6-443F-972F-41A856747F17Q38800092-1B17CACE-6B35-4DBA-BA2D-00C37226F6DEQ38844650-7AF8CFD9-17D0-4914-9614-976D9124B2E2Q38888355-19FEE369-9C96-4DEE-B2A6-BE3E371AB9FCQ38958223-A77F6772-EFB0-453A-89B0-710FC015EFE6Q39182452-FBF7FF94-DBE2-4F49-A12A-9D2D61F70EEEQ39408750-F72E98F7-48C3-4F50-B419-10BA86AB9810Q39683666-091BE701-D6BC-4445-A19A-8E4774CFA773Q39754769-494CB75E-7F58-4BC0-83A0-BCA4DDD1438AQ40260228-1F89603A-13A6-42A2-AB88-9F3608A71A90Q42177328-A136B3F8-8782-4ADA-A3C6-3688CC1093CBQ42800955-ECDD7839-BCA4-4DC6-9164-2940FF3157C8Q44737065-0F1E3F3A-DC48-4DB1-B77D-ADD8F4D7F65CQ46163291-8753EB02-22E9-447E-80AF-DB18EED2BB49Q47633104-EDAE764D-D944-45D2-BDE5-96DCE5AD94D8Q50668713-CB2AF15D-23D1-4E1A-98BF-7286106AF905Q50749129-B1C50144-F35A-46CC-8E38-4BC3759B507DQ50755572-62CF2C7D-1D24-47D2-8640-743BBEBFDD55Q50948205-4A5926E8-42A6-4A8F-A11D-A2AF98D24EDCQ51414946-102D9160-258A-4DFA-8DF4-F58A993F6DB8Q51659233-48D04B0B-10E5-4982-8501-9100E8586D62Q51696345-BA9E6608-CE3A-4AF4-A993-3F6D949AA21BQ51750896-A537D7AC-F0AD-4156-88B4-2EB1AD0C1D7BQ52631865-F9304BD1-8ED9-4597-9BFE-BECC694DFCF3Q55046512-E276921C-E1AB-44E5-B197-0E41C784AF9AQ57988151-189B652E-1464-4619-AE6A-5325887E4F09Q58774865-EE5F4098-624A-4694-B1EC-69E40A3F0490
P2860
Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Transporter studies in drug de ...... tional Transporter Consortium.
@en
type
label
Transporter studies in drug de ...... tional Transporter Consortium.
@en
prefLabel
Transporter studies in drug de ...... tional Transporter Consortium.
@en
P2093
P2860
P356
P1476
Transporter studies in drug de ...... tional Transporter Consortium.
@en
P2093
E Gil Berglund
International Transporter Consortium
P2860
P2888
P304
P356
10.1038/CLPT.2013.77
P407
P577
2013-04-10T00:00:00Z
P5875
P6179
1001504326